In aqueous solutions, beta-cyclodextrin (CD) and cyclodextrin-containing polymers (PolCD) associate with azobenzene-modified polyacrylate (AMP). Inclusion complexes in solution of CD (or PolCD) and AMP, and the viscosity of these mixtures, have been studied as a function of the composition of AMP and concentrations of samples. AMPs are random copolymers containing a low fraction of a light-responsive hydrophobic moieties (< 10 mol % of 6-[4-alkylamido]phenylazobenzene acrylamide), and a charged hydrophilic unit, sodium acrylate. PolCDs are beta-cyclodextrin randomly conjugated with epichlorohydrin and fractionated to yield copolymers of average number of CD per chain equal to 50. In dilute solutions, the composition of complexes has been investigated by capillary electrophoresis and UV-vis spectrometry. Association between PolCD and AMP appears more complex than the conventional Benesi-Hildebrand scheme. We identified a tight (quantitative) binding regime followed by a gradual increase of the density of AMP-bound PolCD upon increasing the concentration of PolCD. At higher concentrations, the formation of large clusters has been characterized by the increase of viscosity by several decades. Light-triggered trans-conformation of the azobenzene moieties of AMPs leads to a marked photoswitch of viscosity. Reversible viscosity swings by up to 6-fold were achieved by alternative exposure to UV and visible lights. In contrast, the composition of PolCD/AMP complexes in dilute regime does not respond to light, though subtle modifications of the structures of complexes are reflected by variation of electrophoretic mobilities and UV spectra. The properties of interpolymer clusters and photoviscosity are accordingly the result of modification of the dynamics of association. In practice, the low concentration of photochrome makes it possible to obtain rapid responses in samples having a thickness of the order of cm. The data reported provide guidelines for the formulations of CD/polymer systems, specifically, viscosity enhancers, which should show promising developments in pharmaceuticals or cosmetics.